Table 2.
Phase | Protocol | Cancer Species | Reference |
---|---|---|---|
I/II | pembrolizumab plus D + T | BRAF-mutated advanced melanoma | NCT02130466 |
I | pembrolizumab plus V + C | BRAF-mutated advanced melanoma | NCT02818023 |
II | sequential V + C and N + I | BRAF-mutated advanced melanoma | NCT02968303 |
II | neoadjuvant N + I | macroscopic stage III melanoma | [89] |
II | anti-PD1 Abs plus denosumab | stage III/IV melanoma | NCT03620019 |
III | vorinostat plus BRAFi/MEKi | resistant BRAFV600E mutant melanoma | NCT02836548 |